AXSM
Axsome Therapeutics Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2015-11-19
$209.92
+7.09 (+3.50%)
last quote
Want the full multi-source brief on AXSM?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$209.92
High
$210.55
Low
$201.54
Previous close
$202.83
Fundamentals
Market cap
$11.32B
P/E (TTM)
—
P/S (TTM)
14.57x
P/B
71.94x
Gross margin
93.24%
Operating margin
-23.96%
Net margin
-24.68%
Rev growth (YoY)
56.87%
EPS growth (YoY)
—
ROE
-255.60%
52W high
$260.19
52W low
$112.90
Beta
0.81x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-02in 59 days
Q3 2026EPS est $-0.41Rev est $263.1M
Recent SEC filings
CIK 1579428filing-language history →
Recent news
2026-08-27 → 2026-09-03
Benzinga · 2d
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $290 price target.
Benzinga · 3d
Axsome Therapeutics Dosed First Patient in SUMMIT Phase 3 Trial of AXS-05 For Smoking Cessation
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial